Skipping sentinel lymph node biopsy may be safe for some early-stage breast cancer pa

[News]

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up, according to results from the BOOG 2013-08 phase III clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

More... (https://www.news-medical.net/news/20251211/Skipping-sentinel-lymph-node-biopsy-may-be-safe-for-some-early-stage-breast-cancer-patients.aspx)